GEN Exclusives

More »

GEN News Highlights

More »
Sep 17, 2012

Life, BMS Ink Long-Term CDx Deal

  • Life Technologies and Bristol-Myers Squibb inked a Master Development Agreement centered on the development of companion diagnostics utilizing Life’s platforms. Under terms of the deal the firms will initially focus on the development of an oncology diagnostic, but the agreement provides for a long-term partnership across a potentially broad range of Life’s instrument platforms and therapeutic areas.

    Life says the partnership, which is its second with BMS, aligns with a strategy to develop its diagnostics business through internal development, partnership, and selected acquisitions. “The pharmaceutical industry is increasingly turning its focus to discovering and delivering targeted, personalized medications,” comments Ronnie Andrews, president of medical sciences. “As more and more targeted drugs come onto the market in the next decade there will be a growing need for diagnostics that can help predict which patients will benefit from which drugs. Life is uniquely positioned to provide pharma a flexible, cost-effective means to manage the evolution of the companion diagnostic assay through the drug development process.”


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?